Red Clover for Hot Flashes: What the Evidence Actually Shows

Red clover (Trifolium pratense) is a flowering legume, best known as pasture forage, that happens to be unusually rich in a class of plant compounds called isoflavones. Isoflavones are phytoestrogens — plant molecules whose shape resembles human estrogen closely enough to bind to estrogen receptors in the body.

Red clover contains four main isoflavones: biochanin A, formononetin, genistein, and daidzein. The first two are unique to red clover in meaningful amounts and are converted in the body into the second two. Soy contains genistein and daidzein directly, which is why red clover and soy are often discussed together — though the profiles are not identical, and results with one do not automatically transfer to the other. We cover the soy side in [soy phytoestrogens for menopause](/blog/soy-phytoestrogens-for-menopause-do-they-work).

The logic behind using it is straightforward. Hot flashes are driven by estrogen withdrawal destabilizing the brain's temperature regulation center in the hypothalamus. If a plant compound can weakly occupy estrogen receptors, perhaps it can take some of the edge off the withdrawal without the risks associated with hormone therapy.

That logic is sound in outline, but it comes with an important qualification. Isoflavones bind far more weakly than human estradiol — orders of magnitude weaker — and they show a preference for estrogen receptor beta over estrogen receptor alpha. Alpha is the receptor most involved in breast and uterine tissue proliferation; beta is more prevalent in bone, brain, and blood vessels. That selectivity is the theoretical basis for hoping isoflavones offer benefit with less risk. It is also the reason the effect on symptoms is modest at best.

This is where the evidence splits, and it is worth understanding why rather than just picking a side.

The skeptical case. In 2013, a Cochrane review led by Lethaby examined phytoestrogens for menopausal vasomotor symptoms across 43 randomized trials. Cochrane reviews are the highest tier of evidence synthesis, and the conclusion was blunt: no conclusive evidence that phytoestrogens, including red clover, relieve hot flashes or night sweats more effectively than placebo. Some individual red clover trials showed a slight reduction in frequency, but the effect did not survive pooled analysis. The review also noted wide variation in trial quality and in the extracts tested.

The more favorable case. A 2017 meta-analysis published in Phytomedicine by Myers and Vigar took a narrower approach. Rather than pooling all phytoestrogens, it examined only trials using a standardized 80 mg red clover extract. Within that tighter group, it found a statistically significant reduction in hot flash frequency compared with placebo. Later meta-analyses focused specifically on red clover isoflavones, including work published in Nutrients in 2021, have reported similar modest benefits.

Why the disagreement? Three reasons. First, "phytoestrogens" is a broad category — pooling soy, red clover, flaxseed, and others may dilute a real effect from one of them. Second, extracts vary enormously in isoflavone content, so "red clover" in one trial is not the same product as in another. Third, hot flash trials have famously large placebo responses, often 30% or more, which makes detecting a small true effect statistically demanding.

The fair summary: if red clover works, it works modestly, in some women, at standardized doses, and the effect is small enough that good studies disagree about whether it exists.

Honestly, poorly — and knowing that up front protects you from spending six months on something unlikely to move the needle when your symptoms are severe.

Hormone therapy remains the most effective treatment for vasomotor symptoms, typically reducing hot flash frequency by around 75% or more in trials. Nothing non-hormonal approaches that.

Fezolinetant (Veozah) and elinzanetant (Lynkuet) are neurokinin receptor antagonists that act directly on the hypothalamic circuit responsible for hot flashes. In their pivotal trial programs — SKYLIGHT for fezolinetant, OASIS for elinzanetant — both produced substantial, statistically robust reductions in frequency and severity. These are prescription medications with a genuine mechanism, and they are covered in [our guide to Veozah](/blog/veozah-fezolinetant-for-hot-flashes-2026-guide).

SSRIs and SNRIs at low doses have solid trial support, including from the MsFLASH research network, and low-dose paroxetine is FDA-approved specifically for hot flashes.

Cognitive behavioral therapy has evidence strong enough that NICE recommends it, and it works on hot flash *bother* and sleep even when frequency changes less — see [CBT for menopause](/blog/cbt-for-menopause-nice-recommended-nonhormonal-treatment).

Black cohosh sits in a similar evidential place to red clover: widely used, mixed data, modest at best. We compare it in [does black cohosh work](/blog/black-cohosh-for-menopause-does-it-work).

Where red clover reasonably fits: mild to moderate symptoms, a preference for trying a supplement first, no contraindications, and realistic expectations. Where it does not fit: severe hot flashes disrupting sleep and work, where trying a supplement for three months mostly costs you three months.

If you decide to try it, the details matter more than with most supplements, because the trials that found benefit used specific standardized products.

Dose. Studies have generally used 40 to 80 mg of total isoflavones per day. The 2017 meta-analysis that found benefit specifically examined 80 mg daily. If a bottle lists only "red clover extract" in milligrams without stating isoflavone content, you cannot know what you are taking — that is the single most common purchasing mistake here.

Standardization. Look for a product stating total isoflavone content per dose, ideally referencing a standardized extract. Herbal supplements are regulated as food rather than medicine in most countries, meaning no requirement to prove that the contents match the label. Third-party testing marks such as USP or NSF are a reasonable proxy for quality.

Timeline. Give it 8 to 12 weeks before deciding. Isoflavone effects, where they occur, build gradually. Judging at three weeks tells you nothing useful.

Measure properly. Because placebo response in hot flash trials runs above 30%, your own impression after a few weeks is unreliable. Count hot flashes for one week before you start — frequency per day and how many wake you at night — then count again in the same way at week 10. Without a baseline you are guessing.

A realistic stopping rule. If you have completed 12 weeks at 80 mg of a standardized extract with no measurable change, stop. Continuing costs money and delays something that might actually work. Our broader review of [menopause supplements that have evidence behind them](/blog/menopause-supplements-that-work-evidence-based-guide) is a good next step.

This is the most important section, and the one most often skipped in product marketing.

Anyone with a history of breast, ovarian, or endometrial cancer, or other hormone-sensitive cancer. Red clover isoflavones are estrogen receptor agonists, however weak. There is no adequate long-term safety data in this population, and the theoretical concern is real. This is a conversation for your oncologist, not a supplement aisle decision.

Anyone taking tamoxifen or an aromatase inhibitor. Phytoestrogens may plausibly interfere with drugs whose entire purpose is blocking estrogen signaling. The clinical data is inconclusive, which is precisely why caution is warranted.

Anyone on anticoagulants. Red clover contains coumarin-related compounds and may increase bleeding risk alongside warfarin or similar medications.

Anyone with liver disease, or taking medications that stress the liver. Herbal preparations are metabolized hepatically and quality control is inconsistent.

Before surgery — stop at least two weeks beforehand because of the bleeding consideration.

During pregnancy or breastfeeding. Not appropriate.

On the endometrium: this is the open question that keeps clinicians cautious. Unopposed estrogen stimulation thickens the uterine lining and raises endometrial cancer risk, which is exactly why systemic HRT in a woman with a uterus always includes progesterone. Most red clover studies have been too short to settle whether long-term isoflavone use has any endometrial effect. Reviews have generally not found endometrial thickening over the durations studied, which is reassuring — but the durations studied are mostly one year or less.

Always tell your doctor. "Natural" does not mean inert, and a supplement that binds estrogen receptors belongs on your medication list.

It is one of the more reasonable supplements to try, and it is nowhere near as effective as it is marketed to be.

What makes it more reasonable than most: there is real randomized trial data, some of it favorable; the safety profile in healthy women over the durations studied looks acceptable; and there is a plausible biological mechanism rather than pure marketing.

What keeps expectations low: the highest-quality evidence synthesis, the 2013 Cochrane review, found no conclusive benefit. The Menopause Society's 2023 nonhormone position statement does not recommend phytoestrogens for vasomotor symptoms — a considered judgment by clinicians who reviewed the same literature. And the benefit found in the more favorable analyses is small in absolute terms.

A practical decision rule:

• •Mild symptoms, curious, no contraindications — a 12-week standardized trial with a proper before-and-after count is reasonable.
• •Moderate to severe symptoms disrupting sleep or work — go straight to a conversation about HRT, fezolinetant, elinzanetant, or an SSRI/SNRI. Do not spend a season on a supplement.
• •Any hormone-sensitive cancer history — talk to your oncology team first, full stop.
• •Already on hormone therapy — there is no established reason to add it.

One thing worth holding onto: the fact that a treatment is modest does not make you wrong for wanting to try it. Wanting to start with the gentlest available option is a rational preference. Just set a clear timeline, measure properly, and be willing to move on. For the broader picture of what is actually driving your symptoms, start with [why hot flashes happen and how to stop them](/blog/menopause-hot-flashes-causes-and-how-to-stop-them).